Welcome to our dedicated page for Zymeworks news (Ticker: $ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zymeworks's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zymeworks's position in the market.
Rhea-AI Summary
Zymeworks Inc. announced the appointment of Dr. Alessandra Cesano to its board of directors, succeeding Dr. Kenneth Hillan. Dr. Cesano brings over 25 years of experience in drug development, diagnostics, and cancer immunology. She will help advance the company's pipeline of novel antibody-drug conjugates and multispecific antibodies. Dr. Cesano currently serves as a director at Puma Biotechnology and Summit Therapeutics, and as the Chief Medical Officer of ESSA Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
-
Rhea-AI Summary
Zymeworks Inc. (ZYME) announced its participation in upcoming investor conferences, including Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, Oppenheimer 34th Annual Healthcare Life Sciences Conference, and Citi's 2024 Virtual Oncology Leadership Summit. The company aims to present its diverse pipeline of novel biotherapeutics for difficult-to-treat diseases, with the management participating in one-on-one meetings and fireside chats. The presentations and webcasts will be available on Zymeworks’ website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
-
Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) provided an update on key strategic priorities for 2024 and 2025, highlighting a cash runway into 2H 2027, top-line data readout from a Phase 3 trial, regulatory reviews for zanidatamab, and progression on their R&D portfolio. The company also announced additional leadership appointments and a presentation at the J.P. Morgan 42nd Annual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) announced significant additions to its leadership team, promoting Dr. Jeffrey Smith to Executive Vice President and Chief Medical Officer, Dr. John Fann to Senior VP, Process Sciences, and appointing seven new Vice Presidents. The company emphasizes its commitment to nurturing internal talent and strengthening its capabilities and experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
-
Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) has entered into a securities purchase agreement with EcoR1 Capital, LLC for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock. The proceeds from this transaction are expected to extend the company's cash runway into H2 2027, providing financial support for the development of novel biotherapeutics and general corporate purposes. The aggregate gross proceeds from the offering are expected to be approximately $50 million, before deducting estimated offering expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.65%
Tags
-
Rhea-AI Summary
Zymeworks Inc. (ZYME) is set to be added to the Nasdaq Biotechnology Index (NBI) on December 18, 2023. The NBI tracks the performance of biotechnology and pharmaceutical companies listed on The Nasdaq Stock Market. Zymeworks' addition to the NBI reflects its eligibility and market performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) to participate in the 42nd Annual J.P. Morgan Healthcare Conference, with one-on-one meetings scheduled on January 8-11, 2024, and a corporate presentation on January 11th, 2024 at 8:15 am Pacific Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
-
Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) reports 44% decrease in net loss for the first nine months of 2023, with cash resources of $390.2 million. Clinical results from Phase 1b/2 study of zanidatamab plus chemotherapy and tislelizumab presented at ESMO Annual Congress. ZW251, a GPC3 targeted antibody drug conjugate, anticipated for IND filing in 2H-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
-
Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME) will participate in upcoming investor conferences including Jefferies London Healthcare Conference, Stifel 2023 Healthcare Conference, and 6th Annual Evercore ISI HealthCONx Conference. The company's management will engage in one-on-one meetings and fireside chats to discuss their novel biotherapeutics. Presentations and webcasts will be available on Zymeworks' website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Zymeworks Inc. to report Q3 2023 financial results and host conference call on November 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
Zymeworks Inc.
Nasdaq:ZYME
ZYME Rankings
ZYME Stock Data
649.23M
41.59M
4.49%
96.15%
7.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
MIDDLETOWN
About ZYME
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.